Publication:
Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy

dc.contributor.coauthorTopkan, Erkan
dc.contributor.coauthorYildirim, Berna Akkus
dc.contributor.coauthorGuler, Ozan Cem
dc.contributor.coauthorParlak, Cem
dc.contributor.coauthorSelek, Ugur
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorPehlivan, Berrin
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:28:00Z
dc.date.issued2015
dc.description.abstractPurpose: To investigate the safety and efficacy of single-dose 8-Gy palliative chest reirradiation (CRI) in metastatic non-small cell lung cancer (M-NSCLC) patients with painful thoracic failures (TF) within the previous radiation portal. Patients and Methods: We retrospectively analyzed the clinical data of 78 M-NSCLC patients who received single-dose 8-Gy CRI for painful TF after concurrent chemoradiation therapy to a total radiation dose of 52 to 66 Gy between 2007 and 2012. Primary endpoints included significant pain relief (SPR) defined as a >= 2 point decrement in the Visual Analogue Scale for Pain inventory (VAS-P), time to pain relief, and duration of pain control. Secondary objectives were survival and prognostic factors. Results: Treatment was well tolerated, with only 5.1% grade 3 pneumonitis and 1.3% grade 2 esophagitis. Pre-CRI median and post-CRI minimum VAS-P were 7 and 3 (P < .001), respectively. SPR was noted in 67 (85.9%) patients, and only 3 (3.9%) scored progressive pain. Median time to lowest VAS-P and duration of pain control were 27 days and 6.1 months, respectively. Median overall survival (OS) was 7.7 months, and the 1-year OS rate was 26.5%. On multivariate analyses, lower Eastern Cooperative Oncology group score (1-2; P < .001), absence of anemia (P = .001), and fewer metastatic sites (1-2; P < .001) were found to be associated with longer OS. Conclusions: Single-dose 8-Gy CRI provides safe, effective, and durable pain palliation for TF in radically irradiated M-NSCLC patients. Because of its convenience, lower cost, and higher comfort, the present protocol can be considered an appropriate option for patients with limited life spans.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume91
dc.identifier.doi10.1016/j.ijrobp.2014.12.010
dc.identifier.eissn1879-355X
dc.identifier.issn0360-3016
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-84924678251
dc.identifier.urihttps://doi.org/10.1016/j.ijrobp.2014.12.010
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11811
dc.identifier.wos351733500017
dc.keywordsOutcomes
dc.keywordsCarcinoma
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physics
dc.subjectOncology
dc.subjectRadiology
dc.subjectNuclear medicine
dc.subjectMedical imaging
dc.titleSafety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorPehlivan, Berrin
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files